EUCTR2006-001904-36-BE进行中（未招募）1 期
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade® versus Velcade alone in Subjects with Relapsed or Refractory Multiple Myeloma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 290
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •To be eligible for the study, subjects must meet all of the following criteria:
- •1. Male or female age = 18 years
- •2. Signed informed consent obtained prior to any study-specific screening procedures
- •3. Confirmed diagnosis of multiple myeloma
- •4. Measurable secretory disease defined as either serum monoclonal paraprotein, (M-protein) =1 g/dL or urine monoclonal (light chain) protein (> 200 mg/24 hours)
- •5. Documented disease progression (according to EBMT criteria) after at least 1 prior line of therapy but no more than 3 or have had no response to previous treatment (primary refractory disease) have undergone or are unsuitable for autologous hematopoietic stem cell transplantation
- •a. A single line of therapy may consist of 1 or more drugs such as, melphalan plus prednisone; vincristine plus conventional doxorubicin (or Doxil/Caelyx) plus dexamethasone (VAD/DVd); lenalidomide; or high-dose pulse corticosteroid with or without thalidomide (rituximab alone or experimental agents alone should not be considered a line of therapy)
- •b. A single line of therapy may include induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance therapy or progression of disease before a response during the initial line of therapy (primary refractory disease) with a regimen that may have contained an anthracycline, an alkylating agent, or high-dose corticosteroids (rituximab alone or experimental agents alone should not be considered a line of therapy
- •6. ECOG performance status score of =2
- •7. Subjects experiencing toxicities resulting from previous therapy must have fully recovered or stabilized to = Grade 1
- •8. Subjects of childbearing potential must use adequate birth control measures. Female subjects of childbearing potential must have a negative serum pregnancy test at screening
- •9. Adequate bone marrow, liver, and renal function at first dose/randomization as described below:
- •a. Hemoglobin = 7.5 g/dL (4.7 mmol/L; 75 g/L) with or without transfusion dependency
- •b. Platelets = 50,000/mm3 without transfusion dependency
- •c. Absolute neutrophil count (ANC) = 1000 mm3 without hematopoietic cytokine support
- •d. AST, ALT, and alkaline phosphatase = 3 x ULN
- •e. Bilirubin = 2 x ULN
- •f. Calculated creatinine clearance = 20 mL/min
- •g. Corrected serum calcium < 12 mg/dL (3.0 mmol/L) or ionized calcium < 6.5 mg/dL (1.6 mmol/L). This level may be achieved by treatment but it must be reached before the subject is randomized
- •10. Able to adhere to study visit schedule and all protocol requirements
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 290
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •Subjects meeting any of the following criteria may not be enrolled in the study:
- •1. Prior treatment with bortezomib
- •2. Hypersensitivity or allergic reactions to boron or mannitol, or compounds containing these components
- •3. Removed the criteria that excluded subjects with prior dexamethasone exposure
- •4. = Grade 2 peripheral neuropathy (according to NCI CTCAE, Version 3.0)
- •5. Treatment with systemic cancer therapy (including clarithromycin) or radiotherapy within 30 days of randomization
- •6. Treatment with nitrosoureas within 42 days of first dose/randomization
- •7. Major surgery within 30 days of first dose/randomization or planning to have surgery (except for minor surgical procedures) during the study
- •8. Received any investigational drug/agent within 30 days or 5 half-lives (whichever is longer) of first dose/randomization
- •9. Received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant
- •10. Has clinically significant residual toxicities associated with prior autologous bone marrow or autologous peripheral blood stem cell transplant
- •11. Administered platelet transfusion or neutrophil growth factor within 2 weeks prior to the collection of screening hematology laboratory sample
- •12. Transplanted solid organ with the exception of a corneal transplant (= 3 months prior to first dose/randomization)
- •13. Received any mAb within 60 days of first dose/randomization
- •14. Serious concurrent illness (medical or psychiatric), uncontrolled infection (including acute, diffuse infiltrative pulmonary disease), or any uncontrolled medical condition (eg, uncontrolled diabetes), including the presence of laboratory abnormalities, that places the subject at unacceptable risk by participating in the study or confounds the ability to interpret data from the study
- •15. Myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class II or higher heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic, clinically significant conduction system abnormalities, baseline QTc interval >450 milliseconds, history of hypokalemia, or any cardiac condition that is = Grade 3
- •16. Prior or concomitant malignancy (other than multiple myeloma) except adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or other cancer for which the subject has been disease-free for = 3 years
- •17. Any other concomitant disease-related treatment such as, immunotherapy, biotherapy, radiotherapy, chemotherapy, investigative therapy, or immunosuppressive therapy/corticoid steroids (other than study specific treatments)
- •18. Vaccinated with live or attenuated vaccines within 4 weeks of the first administration of CNTO 328/placebo
研究者
相似试验
进行中（未招募）
不适用
A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial CystitisBladder Pain Syndrome / Interstitial CystitisMedDRA version: 14.1Level: LLTClassification code 10071166Term: Bladder pain syndromeSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: LLTClassification code 10008928Term: Chronic interstitial cystitis NOSSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: LLTClassification code 10008927Term: Chronic interstitial cystitisSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: PTClassification code 10011796Term: Cystitis interstitialSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-004555-39-NLAstellas Pharma Europe B.V.300
进行中（未招募）
1 期
A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A InfectioEUCTR2015-003002-17-BEJanssen-Cilag International NV90
进行中（未招募）
1 期
A study to investigate how safe and able to produce an effect in the body study drug VX-150 is in patients with pain that typically begins in the feet or handPain Caused by Small Fiber NeuropathyMedDRA version: 20.0Level: PTClassification code 10033371Term: PainSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 20.1Level: PTClassification code 10073928Term: Small fibre neuropathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-001042-10-ITVERTEX PHARMACEUTICALS INCORPORATED89
进行中（未招募）
1 期
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial HypertensioEUCTR2008-007455-26-BEGilead Sciences, Inc.160
尚未招募
2 期
A study to calculate efficacy and safety of SAR441566 in adults with rheumatoid arthritisCTRI/2024/05/067017Sanofi Healthcare India Pvt Limited (SHIPL)